Index

ACCELERATED EXAMINATION
Generally, 29:1 to 29:6
AIA Section 11(h), 29:3
AIA Section 25, 29:3
Amended statutes, 29:3
Congressional intent, 29:2
Fee-based revised examination conditions, 29:6
provisions, 29:5
Initial conditions for fee-based revised examination, 29:6
Non-fee based revised examination provisions, 29:4
17 C.F.R. 1.17(c), 29:6
17 C.F.R. 1.102, 29:6
35 U.S.C. Section 2(b), 29:3
Track One petitions, USPTO statistics on, 29:7

ACT TO CORRECT AND IMPROVE CERTAIN PROVISIONS OF LEAHY-SMITH AMERICA INVENTS ACT
Text, App 7

ACTUAL NOTICE
Marking (this index)

ADMINISTRATIVE LAW JUDGE
AIA Section 21, payment of ALJs, 31:3
AIA SECTION 3(g)(7)(A, B)
Funding agreements, 31:2
AIA SECTION 6(a-c)
Inter Partes Review (this index)
AIA SECTION 6(d)
Post-Grant Review (this index)

AIA SECTION 8(a)
Pre-issuance submissions, 20:3
AIA SECTION 10
Fee setting, 25:3
AIA SECTION 11
Fees, 25:4
AIA SECTION 11(h)
Accelerated examination, 29:3
AIA SECTION 12
Supplemental examination, 22:3
AIA SECTION 13(a)
Funding agreements, 31:2
AIA SECTION 16(a)
Marking, 6:3
AIA SECTION 16(b)
False Patent Marking (this index)
AIA SECTION 17
Enhanced damages and advice of counsel, 10:3
AIA SECTION 18
Covered Business Method Patents (this index)
AIA SECTION 19
Jurisdiction, 12:3
AIA SECTION 20(i)(2)
Funding agreements, 31:2
AIA SECTION 21
Payment of ALJs, 31:3
Travel expenses, 31:3
AIA SECTION 25
Accelerated examination, 29:3
AIA SECTION 26
Study on AIA implementation, 31:4

AIA SECTION 27
Study on genetic testing, 31:5

AIA SECTION 28
Patent ombudsman program, 31:6

AIA SECTION 29
Study on diversity of applicants, 31:7

AIA SECTION 30
Small businesses and inventors, 31:8

AIA SECTION 31
Study on international patent protection for small businesses, 31:9

AIA SECTION 32
Pro bono program, 31:10

AIA SECTION 33
Ban on patents, 4:4
Human organisms, 4:2

AIA SECTION 35
Effective date, 32:2
Enhanced damages and advice of counsel, 10:4

AIA SECTION 36
Budgetary effects, 31:12

AIA SECTION 37(a)
Patent term extension, 30:3

AIA SECTION 37(b)
Patent term extension, 30:2

AIA SECTION 102
Examples of application, 2:11 to 2:22

AMERICAN INVENTOR’S PROTECTION ACT OF 1999
Prior use defense, 8:1

APPEAL AND REVIEW
Reexaminations, ex parte reexaminations, 23:7
U.S. Patent and Trademark Office. PTAB Trial Practice (this index)

APPLICATION DATA SHEET
Assignee filing and inventor’s oath, 24:10

ASSIGNEE FILING AND INVENTOR’S OATH
Generally, 24:1 to 24:11
Amendment regulations, 24:4
statutes, 24:3
Applicant, 24:5
Application data sheet, 24:10
Background, 24:1
Congressional intent, 24:2
Data sheet, 24:10
Declaration, 24:7
Historical perspective, 24:1
Name of inventor, 24:6
New regulations, 24:4
New statutes, 24:3
Oath or declaration, 24:7
Practice, generally, 24:4 to 24:11
Priority claims, 24:9
Substitute statements, 24:8
USPTO recommendations, 24:11

ATTORNEYS
Advice. Enhanced Damages and Advice of Counsel (this index)
PTAB trial practice, 15:6

BACKGROUND
Accelerated examination, 29:1
Assignee filing and inventor’s oath, 24:1
Best mode, 3:1
Covered business method patents, 17:1
Deceptive intent, removal, 27:1
Derivation proceedings, 19:1
CONGRESSIONAL INTENT
—Cont’d
Derivation proceedings, 2:4, 19:2
Ease of determining right to
claimed invention, 2:4
Effective dates, 32:1
Efficiency benefits to applicants,
2:4
Elimination of costly, complex
interference proceedings, 2:4
Enhanced damages and advice of
counsel, 10:2
False patent marking, 9:2
Fee setting and fees, 25:1
First inventor to file, 2:4
Global uniformity of patent laws,
2:1, 2:4
Grace period to inventors, 2:4, 2:6
House Report excerpts, App 1
Human organisms, 4:1
Inter partes reexamination statute,
23:2
Inter partes review, 18:1
Joinder and consolidation, 13:2
Jurisdiction, 12:2
Marking, 5:2
Patent term extension calculation,
30:1
Post-grant review, 16:1
Post-issuance submissions, 21:2
Pre-issuance submissions, 20:2
Prior art, prior to filing date, 2:4
Prioritized examination, 29:2
Prior use defense, 8:2
Progress of science and useful
arts, 2:1
Reexaminations, 23:2
Satellite offices, 28:1
Supplemental examination, 22:2
Tax strategies, limited patent-
ability, 5:1
Venue for review of USPTO deci-
sions, changes, 11:2
CONSIDERED,
RECONSIDERED, OR
CORRECTED
Supplemental Examination (this
index)

CONSOLIDATION
Joinder and Consolidation (this
index)

CONSTITUTIONALITY
First inventor to file system, 2:2

CORRECTION OF
INFORMATION
Supplemental Examination (this
index)

COUNSEL
Advice. Enhanced Damages and
Advice of Counsel (this
index)

PTAB trial practice, 15:6

COVERED BUSINESS METHOD
PATENTS
AIA Section 18, generally, 17:2
Background, 17:1
Checklist for review, 17:7
Civil litigation, effect of CBM
review, 17:11 to 17:14
Congressional intent, 17:1
Content of petition, 17:1
Definition, 1:1
Eligibility to file petition, 17:5
Eligible patents, 17:4
Estoppels, 17:15
Expiration of provisions, 17:3
Final written decisions, 17:10
Petition for CBM review, 17:5 to
17:7
Preliminary injunctions, civil liti-
gation, effect of CBM review,
17:14
Prior art against “first-to-invent”
patents, 17:8
Prior use defense, 8:1
Proceedings, 17:9
final written decisions, 17:10
Restrictions, 17:5, 17:6
Review, generally, 17:1 to 17:11
Statistics, PTAB, 17:16
Stay of litigation, effect of CBM
review, 17:13
COVERED BUSINESS METHOD
PATENTS—Cont’d
Timeliness of petition, 17:6
Venue, civil litigation, effect of CBM review, 17:12

DAMAGES
Enhanced Damages and Advice of Counsel (this index)

DATA SHEET
Assignee filing and inventor’s oath, 24:10

DECEPTIVE INTENT, REMOVAL
Generally, 27:1 to 27:3
Amended statute, 27:2
Background, 27:1
Congressional intent, 27:1
Elimination of defense from litigation, 14:3
35 U.S.C. Section 42 revisions, 27:3

DECLARATORY JUDGMENT ACTIONS
False patent marking, 9:8

DEFINITIONS
Claimed invention, 1:1
Commercial use, 8:1
Competitive injury, 9:5
Covered business method patent, 1:1
Director, 1:1
Effective filing date, 1:1
Inventor, 1:1
Joint inventor, 1:1
Joint research agreement, 1:1
Micro entity, 1:1
Office, 1:1

DERIVATION PROCEEDINGS
Generally, 19:1 to 19:11
Administrative patent judge, 19:7
Arbitration, 19:8
Background, 19:1
Checklist for petition, 19:5

DERIVATION PROCEEDINGS—Cont’d
Common ownership, 19:8
Congressional intent, 19:2
Date invention is made, relevance, 2:8
Effective date, 19:10
Filing petition, 19:5
Institution of proceeding, 19:7
Issued patents, derivation actions between owners, 19:9
Mandatory notice, 19:6
Post-institution of proceeding, 19:8
Preliminary response, 19:6
Proceedings, generally, 19:4
Public availability of Board records, 19:8
Responses, 19:6
Settlements, 19:8
35 U.S.C. Section 135 revision, 19:3 et seq.
35 U.S.C. Section 291, 19:3 et seq.

DIRECTOR
Definition, 1:1

DISCLOSURE
Best mode disclosure requirement, 3:3, App 4
Examples of application of AIA Section 102, 2:11 to 2:22
“Publicly disclosed” identified as definition missing from AIA, 1:2
Removal of consequences for violation of best mode disclosure requirement, 3:3

DISCOVERY
Inter partes review, 18:11
Post-grant review, 16:11
PTAB Trial Practice (this index)
EFFECTIVE DATES
Advice of counsel, AIA provisions, 10:4
AIA Section 35, 32:2
Background, 32:1
Best mode amendments, 3:7
Congressional intent, 32:1
Definition of effective filing date, 1:1
Derivation proceedings, 19:10
First inventor to file, 2:9
Inter partes review, 18:18
Jurisdiction provisions of AIA Section 19, 12:3
Post-grant review, 16:17
Provision, 32:2
Table of AIA effective dates, 32:3

EFFECTIVE FILING DATE
Definition, 1:1

EMBRYOS
Unpatentability of human organism, 4:4

ENFORCEMENT ISSUES
Advice of Counsel (this index)
Best Mode (this index)
Biotechnology composition of matter exception in 35 U.S.C. Section 282, 14:4
Deceptive intent defense, 14:3
Enhanced Damages (this index)
False Patent Marking (this index)
Joinder and Consolidation (this index)
Jurisdiction (this index)
Prior Use (this index)
Venue for Review of USPTO Decisions (this index)

ENHANCED DAMAGES AND ADVICE OF COUNSEL
—Cont’d
Background to new 35 U.S.C. Section 298, 10:1
Congressional intent, 10:2
Discussion of new 35 U.S.C. Section 298, 10:5
Effective date of AIA provisions on advice of counsel, 10:4
Willfulness and advice of counsel, 10:1

ESTOPPELS
Inter partes review, 18:14
Post-grant review, 16:13
Review of covered business method patents, 17:15

EVIDENCE
PTAB Trial Practice (this index)

EXAMINATIONS
Prioritized and Priority Examinations (this index)
Reexaminations (this index)
Supplemental Examination (this index)

EXAMPLES
First Inventor to File, application of AIA Section 102, 2:11 to 2:22
Prior user defense, 8:4
Tax strategies, limited patentability, 5:3

EX PARTES REVIEW
Reexaminations (this index)

EXPERIMENTAL USE
Prior art categories of Section 102(a)(1), 2:6

EXPUNGEMENT OF CONFIDENTIAL INFORMATION
PTAB trial practice, 15:69

FALSE PATENT MARKING
Generally, 9:1 to 9:10
INDEX

FALSE PATENT MARKING
—Cont’d
Activity that is not competitive injury, 9:5
AIA Section 16(b)
amendment of 35 U.S.C. Section 292, 9:3
Constitutional challenges, 9:9
Pending litigation, 9:4
Background, 9:1
Competitive injury
activity that is not competitive injury, 9:5
meaning, 9:5
pleading requirements, 9:6
presumption, 9:6
Congressional intent, 9:2
Declaratory judgment actions, 9:8
Historical perspective, 9:1
Pending litigation, 9:4
Pleading requirements for competitive injury, 9:6
Preemption of state causes of action, 9:10
Presumption of competitive injury, 9:6
Prudential standing to sue for false marking, 9:7
Qui tam action, 9:1, 9:4, 9:9
Standing
declaratory judgment action for no false marking, 9:8
false marking, standing to sue, 9:7
State causes of action, 9:10
Statutory standing to sue for false marking, 9:7
35 U.S.C. Section 292, AIA statutory changes, 9:3

FEES, FEE SETTING AND FEE DIVERSION
—Cont’d
Amended statutes
fee diversion, 26:2
fee setting, 25:2
Background
fee diversion, 26:1
fee setting, 25:1
Congressional intent
fee diversion, 26:1
fee setting, 25:1
Fee diversion, PTO funding
generally, 26:1 to 26:3
background, 26:1
Congressional intent, 26:1
35 U.S.C. Section 42 revisions,
26:3
PTO fee funding, generally, 26:1
to 26:3
PTO fee setting, generally, 25:1 to 25:4
Setting of fees
generally, 25:1 to 25:4
AIA Section 10 fee setting, 25:3
AIA Section 11 fees, 25:4
amended statutes, 25:2
background, 25:1
Congressional intent, 25:1
35 U.S.C. Section 42 revisions,
26:3

FETUSES AND EMBRYOS
Unpatentability of human organism, 4:4

FIRST INVENTOR’S DEFENSE ACT OF 1999
Prior user defense, 8:1

FIRST INVENTOR TO FILE
Generally, 2:1 to 2:22
Applications, 2:9
Congressional intent, 2:4
Constitutionality, 2:2
Contrast of former and current
Section 102, 2:3
Ease of determining right to claimed invention, 2:4
INTER PARTES REVIEW
—Cont’d
Response and amendment by patent owner, 18:8
Settlements, 18:15
Statistics, PTAB, 18:19
Stay of litigation, 18:12, 18:13
Supplemental information, 18:10
35 U.S.C. Sections 311 to 319, generally, 18:1
Three month window
preliminary response by patent owner, 18:5
response and amendment by patent owner, 18:8
Trial proceedings, 18:7
USPTO certificate and intervening rights, 18:16

INTERVENING RIGHTS
Inter partes review, 18:16
Post-grant review, 16:15

INVENTOR
Definition, 1:1

JOINDER AND CONSOLIDATION
Generally, 13:1 to 13:11
AIA Section 19(d), 13:3
Any claim, 13:8
Applicability of Section 299, 13:4
Background, 13:1
Conditions, 13:6
Congressional intent, 13:2
Different products, 13:11
Effective date of Section 299, 13:5
Federal Rules of Civil Procedure,
Rules 20, 21 and 42, 13:1
Historical perspective, 13:1
Inter partes review, 18:9
Multidistrict litigation, 13:17
Multiple products/single defendant, 13:14
Post-grant review, 16:9
Pre-trial proceedings, consolidation, 13:16
Same industry standard, 13:12

JOINTER AND CONSOLIDATION—Cont’d
Same or different products, 13:11
Same patent(s), 13:10
Same transaction, occurrence or series thereof, 13:9
Severance motions, 13:15
Specific applications, 13:9 to 13:14
Specific topics, 13:8
Table of required conditions, 13:6
35 U.S.C. Section 299, generally, 13:3
Trial proceedings, consolidation, 13:16
Venue, joining insignificant parties for, 13:13
Waiverability, 13:18

JOINT INVENTOR
Definition, 1:1

JOINT RESEARCH AGREEMENTS
Common ownership, Section 102(a)(2) exception, 2:7
Definition, 1:1
Prior art exception, 2:4

JUDICIAL REVIEW
Inter partes review, 18:17
Post-grant review, 16:16
U.S. Patent and Trademark Office (this index)

JURISDICTION
Generally, 12:1 to 12:4
AIA Section 19, 12:3
Background, 12:1
Congressional intent, 12:2
Discussion of AIA changes, 12:4
Effective date of AIA Section 19, 12:3
Removal and remand, 12:4
State court jurisdiction, 12:4
28 U.S.C. Section 1295, revision
by AIA Section 19(b), 12:3
JURISDICTION—Cont’d
28 U.S.C. Section 1338, revision by AIA Section 19(a), 12:3
28 U.S.C. Section 1454, new section added by AIA Section 19(c), 12:3

LEAHY-SMITH AMERICA INVENTS ACT
Act to Correct and Improve Certain Provisions of Leahy-Smith America Invents Act, App 7
Text of Act, App 2

LITIGATION
Best mode amendments, 3:5, 3:7
Covered business method patents, effect of review on civil litigation, 17:11 to 17:14
Declaratory judgment actions, false patent marking, 9:8
First inventor to file, former and current versions of Section 102, 2:10
Inter partes review, relationship to civil litigation, 18:12, 18:13
Joinder and consolidation, multidistrict litigation, 13:17
Pending litigation for false patent marking, AIA Section 16(b), 9:4
Post-grant review, relationship to civil litigation, 16:12
Review of covered business method patents, 17:11 to 17:14
Standing to sue for false marking, 9:7
Study of patent litigation by non-practicing entities, AIA Section 34, 31:11

MARKING—Cont’d
Effective date, 6:4
False Patent Marking (this index)
General comments, 6:5
Historical perspective, 6:1
Updating Web site, 6:5
Virtual marking, 6:2, 6:3

MICRO ENTITY
Definition, 1:1

MISMARKING
False Patent Marking (this index)

MISTAKE
PTAB trial practice, 15:53

MOTIONS
PTAB Trial Practice (this index)

MULTIDISTRICT LITIGATION
Joinder and consolidation, 13:17

NAMES
Assignee filing and inventor’s oath, name of inventor, 24:6

OATH OR DECLARATION
Inventor’s oath, 24:7

OFFICE
Defined as U.S. Patent and Trademark Office, 1:1

ON SALE BAR
Prior art categories of Section 102(a)(1), 2:6

ORAL ARGUMENT
PTAB trial practice, 15:47

OTHERWISE AVAILABLE TO THE PUBLIC
Definition missing from AIA, 1:2
Prior art categories of Section 102(a)(1), 2:6
INDEX

PATENT AND TRADEMARK OFFICE
U.S. Patent and Trademark Office (this index)

PATENT OMBUDSMAN PROGRAM
AIA Section 28, 31:6

PATENT TERM EXTENSION
AIA Section 37(a), 30:3
AIA Section 37(b), 30:2
Amended 35 U.S.C. Section 156(d), 30:2, 30:3
Background, 30:1
Calculation of 60-day Period for Application for Patent Term Extension, 30:2
Congressional intent, 30:1
Historical perspective, 30:1

PAYMENT
AIA Section 21, payment of ALJs, 31:3

PENDING LITIGATION
False patent marking, AIA Section 16(b), 9:4

POST-GRANT REVIEW—Cont’d
One month window, 16:7
Preliminary response by patent owner, 16:5
Procedures, 16:3
Rehearing, 16:16
Relationship to civil litigation, 16:12
Settlements, 16:14
Supplemental information, 16:10
35 U.S.C. Sections 321 to 329, generally, 16:2
Three months window
patent owner preliminary response, 16:5
patent owner response and amendment, 16:8
“Trial” proceedings, 16:7
USPTO certificate and intervening rights, 16:15

POST-ISSUANCE SUBMISSIONS
Generally, 21:1 to 21:6
Amended statute, 21:3
Background, 21:1
Congressional intent, 21:2
Filing post-issue citation of art or information, 21:5
35 U.S.C. Section 301, 21:3
37 C.F.R. § 1.501, 21:4
USPTO use of post-issue submission, 21:6

PRE-ISSUANCE SUBMISSIONS
Generally, 20:1 to 20:9
AIA Section 8(a), 20:3
Amended statute, 20:3
Background, 20:1
Congressional intent, 20:2
Filing under 37 CFR Section 1.290, 20:5
Protests under 35 U.S.C. Section 122(c) and 37 CFR Section 1.291, 20:8
Statistics, USPTO, 20:9
Subsequent handling of 37 CFR Section 1.290, 20:7
PRE-ISSUANCE SUBMISSIONS—Cont’d
Survival of protests under 35 U.S.C. Section 122(c) and 37 CFR Section 1.291, 20:8
Third party preissuance submissions, 20:2 et seq.
35 U.S.C. Section 122, 20:3
35 U.S.C. Section 122(c) protests, 20:8
37 CFR Section 1.290, 20:4, 20:5
37 CFR Section 1.291 protests, 20:8
Timing, 20:6

PRELIMINARY INJUNCTIONS
Covered business method patents, civil litigation, effect of CBM review, 17:14

PRINTED PUBLICATION
PTAB trial practice, proof, 15:92
35 U.S.C. section 102, bar to novelty, 2:6

PRIOR ART
Congressional intent, art prior to filing date, 2:4
Grace period
Congressional intent, 2:4
earlier filed application, 2:7
Section 102(a)(1), 2:6
Section 102(a)(2), 2:7
Joint research agreement exception, 2:4
Published applications effective as prior art, 2:7
Section 102(a)(1) prior art categories and exceptions, 2:6
Section 102(a)(2) prior art categories and exceptions, 2:7
Tax Strategies (this index)

PRIORITIZED AND PRIORITY EXAMINATIONS—Cont’d
Congressional intent, 29:2
Fee-based revised examination conditions, 29:6
provisions, 29:5
Initial conditions for fee-based revised examination, 29:6
Non-fee based revised examination provisions, 29:4
17 C.F.R. 1.17(c), 29:6
17 C.F.R. 1.102, 29:6
35 U.S.C. Section 2(b), 29:3
Track One petitions, USPTO statistics on, 29:7

PRIORITY CLAIMS
Assignee filing and inventor’s oath, 24:9

PRIORITY SYSTEM
First Inventor to File (this index)

PRIOR USER DEFENSE
Generally, 8:1 to 8:4
AIA revisions, 8:3
American Inventor’s Protection Act of 1999, 8:1
Analysis of expanded prior use defense, 8:4
Background, 8:1
Burden of proof, 8:4
Business methods, 8:1, 8:4
Change in title of defense, 8:4
Congressional intent, 8:2
Continuity, 8:1
Domestic commercial requirement, 8:1, 8:4
Examples, 8:4
Expanded prior use defense, 8:4
First Inventor’s Defense Act of 1999, 8:1
Good faith, 8:1, 8:4
Limitation on university exception, 8:4
Location, 8:1
Nonderivation requirement, 8:4
Nonprofit laboratory use, 8:4
INDEX

PRIOR USER DEFENSE—Cont’d
Originality, 8:1
Personal defense expansion, 8:4
Personal defense limitation, 8:1
Premarket regulatory review, 8:4
Proof, 8:1
Sanctions, 8:1, 8:4
Site requirements, 8:4
Time, 8:1, 8:4
Type of patent, 8:1, 8:4
University exception, 8:4
USPTO report, 8:4

PRO BONO PROGRAM
AIA Section 32, 31:10

PROGRESS OF SCIENCE AND USEFUL ARTS
First inventor to file system, adoption, 2:1

PROTECTIVE ORDERS
PTAB trial practice, 15:8, 15:9

PTAB TRIAL PRACTICE—Cont’d
Discovery—Cont’d
patent owner’s further discovery period, 15:43
petitioner’s discovery, reply and opposition period, 15:42
Due date
1A, motion to amend claim, 15:40
1B, patent owner’s response to petition and close of discovery and motion period, 15:41
2, petitioner’s discovery, reply and opposition period, 15:42
3, patent owner’s further discovery period, 15:43
4, various motion deadlines, 15:44
5, reply and opposition deadlines, 15:45
6, replies to motions to exclude evidence, 15:46
7, oral argument, 15:47
Evidence
generally, 15:61, 15:62
exclude evidence, motions, 15:46
objections to petition evidence, 15:39
ruling on petition, 15:21, 15:25
Final decision, 15:64 to 15:67
Form of petition and other filings, 15:7
Institution of trial, 15:16
Mandatory notices, preliminary proceeding, 15:5, 15:6
Mistake corrections, 15:53
Motions
generally, 15:56 to 15:60
amending claim, deadline, 15:40
decisions on motions, 15:64 to 15:67
exclude evidence, 15:59
INDEX

REEXAMINATIONS—Cont’d
AIA Section 6(a)-(c), inter partes reexamination, 23:3
AIA Section 6(h), ex partes reexamination, 23:5
Appeal and review, ex parte reexaminations, 23:7
Congressional intent, 23:2
New USPTO Rules
ex partes reexamination, 23:6
inter partes reexamination, 23:4
Reasonable likelihood of success, 23:2
35 U.S.C. Sections 303 and 306,
ex partes reexamination, 23:5
35 U.S.C. Sections 312 and 313,
inter partes reexamination, 23:3

REHEARINGS
Inter partes review, 18:17
Post-grant review, 16:16
PTAB trial practice, requests, 15:68

REMOVAL AND REMAND
Jurisdiction changes, 12:4

SATELLITE OFFICES
Generally, 28:1 to 28:3
AIA provisions, 28:2
Background, 28:1
Congressional intent, 28:1
Discussion of provisions, 28:3

SCHEDULING ORDER
PTAB trial practice, 15:38

SETTLEMENTS
Derivation proceedings, 19:8
Inter partes review, 18:15
Post-grant review, 16:14
PTAB trial practice, 15:63

SMALL BUSINESSES AND INVENTORS
AIA Section 30, 31:8

STATE COURT JURISDICTION
Jurisdiction changes, 12:4

STAY OF LITIGATION
Covered business method patents,
effect of CBM review, 17:13
Inter partes review, 18:12, 18:13

STUDY ON AIA IMPLEMENTATION
AIA Section 26, 31:4

SUBMISSIONS OF ART
Post-Issuance Submissions (this index)
Pre-Issuance Submissions (this index)

SUBSTITUTE STATEMENTS
Assignee filing and inventor’s oath, 24:8

SUPPLEMENTAL EXAMINATION
Generally, 22:1 to 22:9
AIA Section 12, 22:3
Background, 22:1
Benefits, 22:8
Conclusion, 22:7
Congressional intent, 22:2
Content of request, 22:5
General overview, 22:4
New question of patentability,
USPTO determination, 22:6
New statute, 22:3
Request, 22:5
Statistics, USPTO, 22:9
35 U.S.C. Section 257, 22:3
Time for USPTO determination,
22:6
USPTO determination, 22:6

SUPPLEMENTAL INFORMATION
Inter partes review, 18:10
Post-grant review, 16:10

TABLES
AIA effective dates, 32:3
Patentability, table comparing former and AIA-based Section 102, 2:3

Index-15
TAX STRATEGIES

Generally, 5:1 to 5:4
AIA Section 14
analysis, 5:4
statutory provisions, 5:2
USPTO guidance, 5:3, App 6
Congressional intent, 5:1
Electronic tax return preparation, 5:3
Examples, 5:3
Limited patentability, 5:1 to 5:4
Manufacturing hybrid vehicle, 5:3
Payroll processing, 5:3
Prior art, 5:1 to 5:4, App 6
Software related inventions, 5:3
Tax Deferrals, 5:3
Tax reduction, 5:3

THIRD PARTIES

Pre-Issuance Submissions (this index)

35 U.S.C. SECTION 2(b)
Accelerated examination, 29:3

35 U.S.C. SECTION 42
Deceptive intent removal, revisions of statute, 27:3
Fee diversion, PTO funding, 26:3

35 U.S.C. SECTION 102—Cont’d
Grace period
Congressional intent, 2:4
disclosure by actual or joint inventor, 2:6, 2:7
Section 102(a)(1), 2:6
Section 102(a)(2), 2:7
Joint research agreements, common ownership exception, 2:7
One-year grace period, disclosure by actual or joint inventor, 2:6, 2:7
On sale, bar to novelty, 2:6
Otherwise available to public, bar to novelty, 2:6
Printed publication, bar to novelty, 2:6
Prior art
Section 102(a)(1) and exceptions, 2:6
Section 102(a)(2) and exceptions, 2:7
Prior commercial use, historical perspective, 2:6
Public use, bar to novelty, 2:6
Published applications effective as prior art, 2:7
Section 102(a) bars generally, 2:5
Section 102(a)(1), prior art categories and exceptions, 2:6
Section 102(a)(2), prior art categories and exceptions, 2:7
Section 102(b) exceptions from bars, 2:5
Statutory language, 2:5

35 U.S.C. SECTION 103
Amendment of Section 282, 2:8
Obviousness before effective filing date of claimed invention, 2:8

35 U.S.C. SECTION 104
Repealed by AIA Section 3(d), 7:1

Index-16
INDEX

35 U.S.C. SECTION 122
Pre-issuance submissions, 20:3

35 U.S.C. SECTION 122(c) PROTESTS
Pre-issuance submissions, 20:8

35 U.S.C. SECTION 135 Derivation Proceedings (this index)

35 U.S.C. SECTION 157
Repealed by AIA Section 3(e)(1), 7:1

35 U.S.C. SECTION 202
Funding agreements, 31:2

35 U.S.C. SECTION 257 Supplemental examination, 22:3

35 U.S.C. SECTION 273 AIA revisions to prior user defense, 8:3

35 U.S.C. SECTION 282 Biotechnology composition of matter exception, 14:4

35 U.S.C. SECTION 291 Derivation Proceedings (this index)

35 U.S.C. SECTION 292 False patent marking, AIA statutory changes, 9:3

35 U.S.C. SECTION 298 Enhanced Damages and Advice of Counsel (this index)

35 U.S.C. SECTION 299 Joinder and Consolidation (this index)

35 U.S.C. SECTION 301 Post-issuance submissions, 21:3

35 U.S.C. SECTIONS 311 TO 319 Inter Partes Review (this index)

35 U.S.C. SECTIONS 321 TO 329 Post-Grant Review (this index)

37 CFR SECTION 1.290
Pre-issuance submissions, 20:4, 20:5, 20:7
Third party preissuance submissions, 20:4

37 CFR SECTION 1.291 PROTESTS
Pre-issuance submissions, 20:8

TRACK ONE PETITIONS
USPTO statistics on, 29:7

TRAVEL EXPENSES
AIA Section 21, 31:3

TRIGGER DATE
First inventor to file, 2:9

28 U.S.C. SECTION 1295 Jurisdiction, revision by AIA Section 19(b), 12:3

UNITED STATES DISTRICT COURT OF EASTERN DISTRICT OF VIRGINIA Venue for review of USPTO decisions, 11:4

UNIVERSITY PATENT Date invention is made, relevance, 2:8

U.S. PATENT AND TRADEMARK OFFICE
Appellate review of USPTO actions generally, 11:1
Venue for Review of USPTO Decisions (this index)
Assignee filing and inventor’s oath, USPTO recommendations, 24:11
Best mode, applicable USPTO final rules, 3:4
Definition of Office, 1:1
Ex partes reexamination, new USPTO Rules, 23:6
Fees, Fee Setting and Fee Diversion (this index)
<table>
<thead>
<tr>
<th>U.S. PATENT AND TRADEMARK OFFICE — Cont'd</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Human organism” patent ban, USPTO interpretation, 4:3</td>
</tr>
<tr>
<td>Inter partes reexamination, new USPTO Rules, 23:4</td>
</tr>
</tbody>
</table>

Non-trial proceedings

- **Post-Issuance Submissions** (this index)
- **Pre-Issuance Submissions** (this index)
- **Reexaminations** (this index)
- **Supplemental Examination** (this index)

Office defined, 1:1

**Reexaminations** (this index)

**Supplemental Examination** (this index)

Trial proceedings

- **Covered Business Method Patents** (this index)
- **Derivation Proceedings** (this index)
- **Inter Parties Review** (this index)

<table>
<thead>
<tr>
<th>U.S. PATENT AND TRADEMARK OFFICE — Cont’d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial proceedings—Cont’d</td>
</tr>
<tr>
<td><strong>Post-Grant Review</strong> (this index)</td>
</tr>
<tr>
<td><strong>PTAB Trial Practice</strong> (this index)</td>
</tr>
</tbody>
</table>

**VENUE FOR REVIEW OF USPTO DECISIONS**

Generally, 11:1 to 11:4

AIA Section 9, 11:3, 11:4

Background to venue changes, 11:1

Congressional intent in venue changes, 11:2

Historical perspective to venue changes, 11:1

Technical amendments relating to venue, 11:3

United States District Court of Eastern District of Virginia, 11:4

**WELDON AMENDMENT**

Unpatentability of “human organisms,” 4:1